Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

Leaky Scanning

Leaky Scanning

During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R stands for...

Initiation of Translation

Initiation of Translation

Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...

Recombinant DNA

Recombinant DNA

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sequence-Optimized mRNA Vaccines Against Infectious Disease.

Methods in molecular biology (Clifton, N.J.)·2024

Same author

Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses.

Vaccines·2022

Same author

Historic nucleic acids isolated by Friedrich Miescher contain RNA besides DNA.

Biological chemistry·2021

Same author

Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial.

Wiener klinische Wochenschrift·2021

Same author

CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2.

Nature communications·2021

Same author

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents.

NPJ vaccines·2021

Search research articles

Related Experiment Video

Updated: May 17, 2026

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles

Published on: August 17, 2022

Developing mRNA-vaccine technologies.

Thomas Schlake¹, Andreas Thess, Mariola Fotin-Mleczek

¹CureVac GmbH, Tübingen, Germany. rna-vaccine-rev-2012@curevac.com

|October 16, 2012

Summary

Messenger RNA (mRNA) vaccines offer a flexible and safe platform for genetic vaccines, inducing balanced immune responses without MHC haplotype restriction. This technology shows promise as a game-changing vaccine platform.

Keywords:

adjuvant formulation mRNA mRNA design mRNA production mRNA uptake protein expression vaccine

More Related Videos

Synthesis and Characterization of mRNA-Loaded Poly(Beta Aminoesters) Nanoparticles for Vaccination Purposes

Synthesis and Characterization of mRNA-Loaded Poly(Beta Aminoesters) Nanoparticles for Vaccination Purposes

Published on: August 13, 2021

Related Experiment Videos

Last Updated: May 17, 2026

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles

Published on: August 17, 2022

Synthesis and Characterization of mRNA-Loaded Poly(Beta Aminoesters) Nanoparticles for Vaccination Purposes

Synthesis and Characterization of mRNA-Loaded Poly(Beta Aminoesters) Nanoparticles for Vaccination Purposes

Published on: August 13, 2021

Area of Science:

Vaccinology
Molecular Biology
Immunology

Background:

Messenger RNA (mRNA) vaccines present a novel approach to vaccine development.
They offer a unique combination of immunological benefits and safety.
Existing vaccine technologies face limitations that mRNA can address.

Purpose of the Study:

To review the current knowledge on mRNA vaccine technology.
To highlight the advantages and considerations for developing mRNA-based vaccines.
To establish mRNA as a promising vaccine platform.

Main Methods:

In situ protein expression.
Induction of cellular and humoral immunity.
Assessment of safety and flexibility.

Main Results:

mRNA vaccines induce balanced immune responses (cellular and humoral).
They are not subject to MHC haplotype restriction.
mRNA is a safe, transient, and non-genomic interacting vector.
Maximum flexibility in protein expression and development is achieved.

Conclusions:

mRNA technology offers a promising and flexible platform for next-generation vaccines.
Its safety profile and ability to induce robust immunity make it a game-changer.
Further development of mRNA-based vaccines is warranted.